Bifogade filer
20251028_Isofol_Invitation investor meeting November 13
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, October 28, 2025 - Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) hereby invites investors and shareholders to an investor meeting for updates on the latest events for the company and the drug candidate arfolitixorin.
The information in the press release is intended for investors.
Isofol is developing arfolitixorin – a proprietary clinical-stage drug candidate designed to enhance the efficacy of established cancer treatments. Based on extensive clinical research, arfolitixorin is now being tested in a phase Ib/II clinical study with an optimized dose regimen, conducted at the German University Hospital Charité – Universitätsmedizin Berlin. The drug candidate has the potential to fill a known treatment gap in cancer care.
Isofol invites to an investor meeting to provide an update on the company's ongoing clinical study with the drug candidate arfolitixorin. The meeting will be held in Gothenburg but can also be followed online. The presentation is mainly held in Swedish and an English version will be available on the website after the event. Participants will have the opportunity to ask questions, both on site and online.
Date and time
Thursday November 13, at 17.00-18.00 (webcast)
Venue
Arvid Wallgrens Backe 20, 5th floor, Gothenburg and webcast
Agenda
16.30-17.00
Registration
17.00-18.00
Update on the company and the ongoing Phase Ib/II clinical study
Q&A
18.00-19.00
Mingle and refreshments
Registration
You are welcome to register via the company’s website, no later than November 7:
https://isofolmedical.com/investor-meeting-november-13-2025/
Please note that the number of seats is limited at the venue. When the registration period has expired you will receive a confirmation by e-mail with a web link included if you want to follow the investor meeting online. This link will be published on Isofol’s website after November 7.
An English presentation will also be available on Isofol’s website afterward.
For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56
The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on October 28, 2025.
About Isofol
Isofol works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.